ArticleHaematologica2019

Venetoclax plus rituximab or obinutuzumab after allogeneic hematopoietic stem cell transplantation in chronic lymphocytic leukemia.

Othman Al-Sawaf et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.